03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other molecule...
16:02 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and mouse studies suggest inhibiting the IL-6-JAK-STAT3 axis could help treat FGF19-driven hepatocellular cancer (HCC). In HCC patients, high tumor levels of FGF19 were associated with poor overall survival and...
08:00 , Feb 18, 2010 |  BC Innovations  |  Targets & Mechanisms

Turning up the heat on HD

Researchers at Duke University have found small molecules that help cells untangle aggregates of the misfolded protein thought to cause Huntington's disease.1 The molecules are now the lead compounds for Chaperone Therapeutics Inc., a neurology...
07:00 , Mar 12, 2009 |  BC Innovations  |  Targets & Mechanisms

Hitting Hsp90 where it hurts

Researchers at the University of Massachusetts Medical School have synthesized a class of targeted molecules called gamitrinibs that selectively inhibit Hsp90 in tumor mitochondria, the organelle where Hsp90 exerts many of its cancer-promoting effects. The...